No details found..
There is no data available. Please consult doctor before consuming the drug.
Interaction with alcohol is unknown. Please consult your doctor.
Fertihope m tablet may be unsafe to use during pregnancy. Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor. WEIGH RISKS VS. BENEFITS
Take during or immediately after the meals and consume slowly. Take at evenly spaced times throughout the day (every 3 or 4 hours). Monitor your blood glucose levels regularly during levocarnitine treatment. Take precautions during levocarnitine treatment as you may be at risk of bleeding. Do not take this drug if you are allergic to levocarnitine or any of its ingredients. Tell your doctor if you are pregnant, planning to become pregnant or are breastfeeding.
Fertihope m tablet is probably unsafe to use during breastfeeding. Please consult your doctor.
No details found..
Once A Day:90%|Twice A Day:10%
Nausea, Palpitations, Paresthesia (tingling or pricking sensation), Peripheral edema, Gastrointestinal discomfort, Anemia, Muscle pain, Bone pain, Bronchitis, Cough, Diarrhoea, Gastritis, Headache, Increased calcium level in blood, Increased blood pressure, Muscle weakness, Tachycardia, Vertigo, Vomiting
Levocarnitine belongs to the class of medications called as amino acid derivative. It works by improving the low levels of carnitine in the body.
Q. What is levocarnitine?|Levocarnitine is a type of protein. It is used to treat primary and secondary levocarnitine deficiency. Carnitine deficiency occurs when the body has a shortage of levocarnitine. |Q. How does levocarnitine work?|Levocarnitine is a type of protein. It is used to treat primary and secondary levocarnitine deficiency. Carnitine deficiency occurs when the body has a shortage of levocarnitine. |Q. What does levocarnitine treat?|Levocarnitine is a type of protein. It is used to treat primary and secondary levocarnitine deficiency. Primary systemic carnitine deficiency is characterized by low concentrations of levocarnitine in plasma, red blood cells, and/or tissues. Secondary carnitine deficiency can be a consequence of inborn errors of metabolism.